Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06383559
Status:
RECRUITING
Last Update Posted:
2024-04-25
First Post:
2024-04-22
Brief Title:
Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients a Multi-center Prospective Single-arm Phase II Trial
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center prospective open label phase 2 study evaluating the safety and efficacy of standard first-line chemotherapy XELOX regimen combined with Sintilimab anti-PD-1 antibody and Lenvatinib in the treatment of advanced AFP-positive gastric cancer This study was conducted in the Department of Gastrointestinal Medical Oncology Tianjin Medical University Cancer Institute and Hospital Previous phase 1 dose escalation study TJMUCH-GI-GC002 has demonstrated that such combinational pattern was well tolerated with promising efficacy In this study patients with AFP-positive and HER-2-negative advanced gastric cancer who had not received palliative systematic treatment in the past will be enrolled Patients who met the inclusion criteria were treated with XELOX regimen combined with Sintilimab plus Lenvatinib every 3 weeks until disease progression or intolerable adverse reactions or death The treatment regimen is XELOX chemotherapy oxaliplatin 130mg m2 d1 capecitabine 850-1250 mgm2 bid d1-14 every 3 weeks in combination with Sintilimab 60kg 200 mg 60kg 3mgkg intravenous infusion every 3 weeks plus Lenvatinib determined from previous phase 1 study 16mg orally once a day Patients received regular and periodic reviews with imaging evaluations every 6 weeks Safety will be evaluated by AE and laboratory tests
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None